The aim of the study is to evaluate early safety, clinical efficacy and long-term outcomes of mitral allografts and stented biological prosthesis in tricuspid valve replacement for primary tricuspid valve diseases.
Patients with primary tricuspid valve disease and/or tricuspid bioprosthetic failure scheduled for tricuspid valve intervention.
Intraoperative findings suggested for tricuspid valve replacement rather than repair.
Pregnancy
Confirmed active drug addiction
Progressive HIV-infection
HIV-infected patients with CD4-cells count less than 250
Patients with primary tricuspid valve disease and/or tricuspid bioprosthetic failure scheduled for tricuspid valve intervention
Case-control
Retrospective
tricuspid valve replacement
Procedure/SurgeryComplete or partial tricuspid valve replacement with mitral allograft/ complete tricuspid valve replacement with biological prosthesis
Mortality
Freedom from all-cause mortality (%)
Stroke
Stroke rate (n,%)
Severe valve dysfunction
Number of patients free from peak valve gradient more than 6 mmHg and severe valve regurgitation (vena contracta no more than 6 mm), (n,%)
Freedom from prosthetic endocarditis
Number of patients free from prosthetic endocarditis (n,%)
Transvalvular gradient
Peak and mean gradient (mmHg)
Transprosthetic regurgitation
Vena contracta (mm)
Right atrial remodeling
right atrium size (mm)
Click on the lead sponsor to view all of their trials.
